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Abstract Growth hormones are proteins produced by the
anterior pituitary gland responsible for bone and tissue
growth through their effects on carbohydrates, lipids and
proteins metabolisms. Despite strict regulations banning
the use of recombinant equine growth hormone, this sub-
stance is suspected to be misused to improve the horse
physical performances. In order to check whether the
regulation is fulfilled or not, controls are organized and a
new analytical screening tool potentially able to detect such
abuse was investigated in this paper. An untargeted meta-
bolomics approach, based on liquid chromatography cou-
pled to high resolution mass spectrometry, was developed
and applied to characterize and compare horse urinary and
plasmatic metabolic profiles upon reGH administrations.
After minimal sample preparation, biological fluids were
analyzed by LC-ESI(±)-Q-TOF. Data processing was
performed by XCMS software and multivariate data anal-
ysis applied to the generated data set allowed building
OPLS models to discriminate control versus treated
populations. Results demonstrated significant metabolic
modifications consecutively to the reGH treatment. A
comparative study between urinary and plasmatic signa-
tures was performed to evaluate the resulting metabolomic
models and to asses their respective interests in the scope
of real application for screening reGH administration.
Keywords Growth hormone  Horse racing 
High resolution mass spectrometry  Metabolomics
Abbreviations
GH Growth hormone
reGH Recombinant equine growth hormone
IGF-I Insulin like growth factor-I
LC Liquid chromatography
ESI Electrospray ionization
MS Mass spectrometry
1 Introduction
Growth hormones (GH), also named somatotropins (ST),
are around 190 amino acids polypeptides produced by the
anterior pituitary gland of mammals (Rahmanian et al.
1997). If GH is primarily responsible for bone and tissue
growth, this molecule exhibits also many other biological
effects associated with developmental and reproductive
functions (Thompson 1997; Etherton and Bauman 1998).
For health safety and economical reasons, available growth
hormones are nowadays recombinant molecules. Recom-
binant equine growth hormone (reGH) was first marketed
in Australia (EquiGen-5) in order to improve the positive
nitrogen balance in horses over 15 years (Malinowski et al.
1997). However, it is also suspected to be diverted from
its original purpose to improve physical performance and
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wound healing (Dart et al. 2003). In this context, the racing
rules have strictly prohibited the use of recombinant equine
growth hormone in France. In order to check whether the
regulation is fulfilled or not, controls have been organized
and efficient methods based on mass spectrometry detec-
tion have been set up. To date, the screening of reGH
administration focuses on specific biomarkers such as
Insulin-like growth factor-1 or antibodies anti-reGH (Popot
et al. 2001;(Bailly-Chouriberry 2008a) whereas confirma-
tion methods relies on LC–MS/MS measurement of the
reGH itself in plasma (Bailly-Chouriberry 2008b).
Despite their efficiency, the current screening strategies
for controlling their potential illegal use face some limits
such as the establishment of biomarkers thresholds or
the delay necessary before inducing an immunological
response, which are both animal dependant. Since growth
hormone acts on many action sites via carbohydrate and
lipidic metabolisms (Szeszycki et al. 1996), a wide range of
potential biomarkers could be expected to be monitored for
such screening analysis. In this context, metabolomics may
represent a new emerging approach for investigating the
global physiological effects associated to the administra-
tion of growth hormone and therefore constitute an alter-
native screening strategy.
Metabolomics, also known as global metabolomic pro-
filing, basically consists in the untargeted study of relatively
polar and low molecular weight compounds (typically \
1500 Da) present in biological samples and accessible to
the analysis (Nicholson et al. 2002). Since these so-called
metabolites are the end-products of cellular regulatory
processes, and since their levels can be regarded as the
ultimate response of biological systems to any changes,
studying the metabolome through biological fluids (meta-
bolic profiling or fingerprinting) is expected to reveal
potential metabolomic disruption and therefore highlight
relevant biomarkers of exposure or effect associated to drug
administration. Two main analytical techniques are pre-
dominantly reported and described in metabolomics stud-
ies: 1H nuclear magnetic resonance spectroscopy (NMR)
(Nicholson et al. 1999) and gaz or high-performance liquid
chromatography coupled to mass spectrometry (Bajad and
Shulaev 2007; Theodoris et al. 2008). NMR which has
traditionally been used in this context present clear advan-
tages in terms of robustness and reproducibility but MS
based methods have recently proved to be valuable for such
studies, especially thanks to recent technological advances
(Tolstikov and Fiehn 2002; Tolstikov et al. 2003; Idborg
et al. 2005) and furthermore present some incomparable
advantages over NMR either in terms of sensitivity or
capabilities for structural elucidation purposes. Several
ionization/desorption techniques have been used in MS
metabolomics, including FAB (Platt et al. 1988), MALDI
(Jarman et al. 2000) or Electrospray (McDougall et al.
2008). High resolution mass analysers such as time of flight
(TOF) (Kind et al. 2007), Fourier transform ion cyclotron
resonance (Sleighter and Hatcher 2007) and the recently
introduced LTQ-Orbitrap analysers (Dunn et al. 2008) then
remains the instruments of choice in this field.
The first metabolomics studies were originally and pri-
marily focused on clinical (Kind et al. 2007; Lewis et al.
2008) or pharmaceutical applications (Robertson 2005) but
new more specific areas of application have recently
emerged, for instance in the anti-doping field. In this specific
domain, metabolic variations induced by physiological
response to hormonal treatment have already been investi-
gated and evidenced using NMR (Dumas 2002a, b). These
two particular studies were the first to demonstrate the suit-
ability of a metabolomics strategy as a powerful tool to
screen for anabolic steroid administration in cattle. More
recently, a study based on LC-HRMS urinary fingerprints
demonstrated the relevance of such an untargeted meta-
bolomics approach to discriminate control versus clenbu-
terol treated calves (Courant et al. 2009). Regarding the
growth hormone issue, a similar study was successfully
reported to highlight metabolomic perturbations associated
with reGH treatment (Kieken et al. 2009) through LC-HRMS
urinary biological signatures. This preliminary study aimed
at assessing the feasibility of such an approach in the context
of growth hormone abuse in horses, was however conducted
on a relatively reduced number of animals. In addition, if
urine is often reported as a matrix of interest in such studies
since it is a fluid of excretion containing a large number of
potential interesting metabolites which can easily be col-
lected (Courant et al. 2009; Kieken et al. 2009; Rijk et al.
2009), the use of plasma is also reported in many applications
and has demonstrated its relevance in the discovery of new
biomarkers (Giovane et al. 2008; Liu et al. 2009).
In this context, the aim of the present work was to
generate and compare plasmatic LC-HRMS fingerprints of
low molecular weight metabolites collected from control
and GH-treated horses to assess the global biological effect
consecutive to reGH-treatment by means of chemometric
models. Analyses were conducted either in positive and
negative ionization electrospray mode in order to investi-
gate different sub-fraction of the metabolome. Finally, a
urine profiling study was also performed to compare and
assess the two respective chemometrics models, and then
the relevancies of the two biological matrices.
2 Materials and methods
2.1 Chemicals and reagents
Recombinant equine growth hormone, reGH (EquiGen-5)
was purchased from BresaGen Ltd (Thebarton, Australia).
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HPLC grade acetonitrile (MeCN), acetic acid, and ammo-
nium acetate were purchased from Carlo Erba Reactifs
(SDS, Peypin, France). d3-testosterone and d3-epi-testos-
terone-glucuronide were obtained from LGC Standards
(Molsheim, France). Deionised water was produced using
an ultra pure water system (Milli-Q, Millipore Corporation,
Billerica,USA).
2.2 Animals, treatment and sample preparation
Experimentation was led in agreement with animal welfare
rules at the National Veterinary School of Toulouse
(France). Thirteen standarbred horses (5 mares and 8
geldings) weighting from 430 to 610 kg and aged between
4 and 20 years-old have been used and divided in two
groups, assigned as control and treated animals. Adminis-
trated horses received reGH by subcutaneous injection at
18 lg kg-1 during 14 days and the control group was
administrated with the excipient only. In both groups,
plasma and urine samples were collected daily during the
week preceding the first injection (i.e. days D-7 to D-1)
and during the three-first weeks after the first injection (i.e.
days D?1 to D?20). Samples were then collected every
2 days until D?69. Samples were stored at -20C until
analysis. ReGH doses were chosen according to the rec-
ommendations of the manufacturer.
2.3 Sample preparation
The sample preparation was based on the filtration of
biological samples (plasma and urine) through a 10 kDa
polyethersulfone membrane (Microsep 10 K Omega,
VWR, Fontenay sous bois, France) under centrifugation at
4000 rpm at 5C for 30 min. The filtered samples were
then frozen at -20C. Before LC-HRMS analyses, 5 ll of
a solution containing two internal standards (d3-testosterone
and d3-epi-testosterone-glucuronide), both at 3 ng ll-1,
were added to 20 ll of each sample. The mixture was
shaken and 5 ll of this solution were injected on the LC
system.
2.4 LC-HRMS analysis
2.4.1 Liquid chromatography
Chromatographic separation was performed with an Ulti-
mate 3000 (Dionex, Sunnyvale, USA) pump on a reversed
phase (2.1 mm 9 100 mm Uptisphere Strategy NEC,
2.2 lm particle size, Interchim, Montluc¸on, France). The
analytes were eluted by a 20 min gradient, started at 100%
A (Water ? 0.1% acetic acid) to 100% B (Acetoni-
trile ? 0.1% acetic acid) in 13 min, was maintained at 100%
B during 1 min and then returned to the initial condition
within 4 min. The chromatographic system was further
maintained at 100% A during 2 min (equilibration time).
2.4.2 ESI-HRMS
High-resolution MS fingerprints were acquired on a hybrid
mass spectrometer (MicroToF Q-II, Bruker, Bremen,
Germany) in both positive and negative electrospray ioni-
zation mode. The capillary voltage was set at 5 kV. The
other spectrometric parameters were set as follows: capil-
lary temperature: 180C, nebulizer ‘‘gas flow’’: 2.4 bar, dry
‘‘gaz flow’’: 8 L min-1. A solution of sodium cluster was
used for external calibration of the instrument. For analyses
performed in negative mode, the value of capillary voltage
was changed and set at 3.5 kV, the other parameters
remained unchanged. Centroid full scan mass spectra were
acquired in the [200–1500] and [50–800] mass ranges for
plasma and urine samples analysis, respectively.
2.5 Data processing
After LC-HRMS analysis, the original data files were
converted to the NetCDF format (.cdf) for further data
processing using a conversion software program (file
converter program available from Bruker Daltonics Data
Analysis software).
The data processing was achieved using XCMS (Smith
et al. 2006) software implemented with the R statistical
language, as described elsewhere (Kieken et al. 2009).
Briefly, the process is based on several steps: peak picking,
peak grouping, retention time alignment followed by a first
statistical test which is performed on the whole data set to
calculate the P value and the fold change associated to each
detected MS signal. This step is based on the comparison of
the MS signal abundances of extracted ions present in both
control and GH-treated populations. Finally, the signals are
attributed a rank according to their P value.
2.6 Data analysis
As previously described (Kieken et al. 2009) SIMCA-
P ? (v 12.0, Umetrics, Sweden) software was used for
multivariate data analysis. Orthogonal Partial Least Square
(OPLS) analyses were applied to build descriptive and
predictive models. These OPLS models attempt to explain
and predict one Y variable (in our study the status of the
animals involved, i.e. GH-treated or Control) from a
X matrix constituted by all the ions constituting the fin-
gerprints. The two main components generated by the
analysis are as follows: axis 1 (= [t1]) is a linear combi-
nation of ions selected after data processing, it aims at
better explaining the discrimination between GH-treated
and control animals; axis 2 (= [t2]), orthogonal to axis 1, is
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a linear combination of the ions detected during data pro-
cessing which aims at restoring the residual variability. The
validity and robustness of models were evaluated by
R2(Y) and Q2(Y) parameters, cross validation, permutation
test and CV-ANOVA.
3 Results and discussion
3.1 Quality of LC-HRMS data
If in conventional target compounds analysis, the quality of
the data produced are controlled by the incorporation of
internal standards and specific quality control samples
(QCs) which are often blank samples spiked with known
concentrations of the target analytes, this kind of approach
is much more difficult in metabonomics analysis where the
samples typically contain 100 s – 1000 s of components
covering a wide range of concentrations and structural
types, of variable and unknown MS responses. It is however
important to control the quality of the data produced;
therefore several quality controls have been introduced in
the present study. Pools of samples were injected at the
beginning, the end but also randomly all along the analyt-
ical run in order to check for consistency during analysis. In
addition, two ‘‘internal’’ standards (d3-testosterone and
d3-epi-testosterone-glucuronide) have been added to each
sample before LC-HRMS analysis in order to evaluate the
retention time stability, the consistency of signal intensities
and mass accuracy within and between measurement series.
No significant drift in retention time was observed within
and between measurement series; the deviation from stan-
dard accurate masses remained below 5 ppm.
3.2 Investigation of plasma metabolome under ESI?
Ninety-six plasma samples were filtered under 10 kDa cut-
off membranes, which is a sample preparation already
assessed in previous works regarding its relevance for
metabolomics study (Courant et al. 2009; Kieken et al.
2009). The samples were then analyzed by LC-HRMS in
positive electrospray ionization. Centroid full scan mass
spectra were acquired in the [200–1500] mass range,
adapted to the analysis of soluble substances present in the
plasma such as carbohydrates, lipids or small proteins. The
choice of a chromatographic separation step was naturally
imposed given the complexity of the plasma matrix.
However, phase particles of small size (2.2 lm) were used
to reduce the length of the analysis as compared to the
protocol presented in a previous study (Kieken et al. 2009).
LC-HRMS data were then processed by XCMS software
and 5086 ions exhibiting signal-to-noise ratio better than 6
were reported as constituting the acquired metabolic
fingerprints. A supervised multivariate analysis OPLS
(Orthogonal Partial Least Square) was then performed on
the basis of all acquired metabolic fingerprints in order to
set up a descriptive model. The resulting model (Fig. 1a)
clearly shows that plasma samples collected from control
animals (m0) have coordinates opposed to plasma samples
collected from GH-treated horses (m1) which leads to their
good visual discrimination on the figure. These good
performances were confirmed by the high values found for
R2(Y) = 0.85 and Q2(Y) = 0.50.
In the scope of targeting candidate biomarkers of reGH
administration, a selection of ions more particularly
involved in the discrimination of control and GH-treated
populations was performed from the OPLS model pre-
sented in Fig. 1a. First, the so-called ‘‘S-plot’’ associated to
this model was examined to visualize the contribution of
each ion to the model and thus highlight which of them
were the most correlated to the first discriminant compo-
nent (Fig. 2). A particular attention was paid to those ions
and furthermore, only those exhibiting P value lower than
0.05 and fold change higher than 1.5 were selected. Finally,
a visual examination of the XCMS overlaid extracted ions
chromatograms was completed in order to eliminate any
potential artefacts MS signals. The successive application
of all these criteria finally led to the selection of 56 ions.
A new OPLS analysis was then performed on the basis
of these 56 selected ions which shows the possibility to still
separate plasma collected from control (m0) or GH-treated
animals (m1) with acceptable descriptive (R2(Y) = 0.7)
and predictive (Q2(Y) = 0.5) capabilities (Fig.1b). Only
samples collected from treated animals 69 days after the
first reGH administration cannot be discriminated from
control population (black circle) which may be explained
by the fact that metabolic perturbations associated to reGH
administration are no longer detectable on the basis of 56
selected ions. The robustness of this model was further
investigated by several steps. First, a cross-validation was
performed. It consists to build a new OPLS analysis on the
basis of 2/3 of the original dataset. The other 1/3 of the
dataset is considered as validation test and is incremented
in the model for the prediction. The results (Fig. 3 a) are
satisfactory since they show the possibility to build a
reliable descriptive model (R2(Y) = 0.78 Q2(Y) = 0.51)
where control (m0) and GH-treated (m1) populations are
discriminated. Moreover, the prediction of the remaining
data composed of control animals (j2) and GH-treated
animals (j3) allowed the classification of these samples
without misallocation. The cross-validation thus demon-
strates that the model could be used as a future predictive
tool for the classification of unknown samples. Neverthe-
less, a permutation test must be absolutely performed to
ensure that these results are not due to a chance factor. It
consists in reallocating randomly the status of the animals
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(i.e. control or GH-treated). Figure 3b shows that
R2(Y) and Q2(Y) values decrease upon permutations which
demonstrate that the model is not the result of a chance
factor but a valid and robust discrimination between con-
trol and reGH-treated populations. Finally a CV-ANOVA
(Cross Validation-ANaysis Of Variance) was calculated. It
allows attributing a degree of significance to the test-per-
mutation. The results of CV-ANOVA variant suggest that
the model is significant with a P value of 0.004.
3.3 Investigation of plasma metabolome under ESI-
Plasma samples were also analyzed after negative elec-
trospray ionization mode but maintaining all other
acquisition parameters identical. During the data process-
ing step, 3039 ions constituting the fingerprints were
extracted by XCMS and further subjected to multivariate
statistical analyses (Fig. 4a). An efficient discrimination
was observed between control and GH-treated animals with
high R2(Y) = 0.85 and Q2(Y) = 0.7 values. A focus on the
ions the most involved in the discrimination of control
(m0) and GH-treated animals (m1) was carried out. In the
same manner as for the analysis conducted in positive
ionization mode, only ions strongly correlated to the first
discriminant component, and presenting P value lower than
0.05 as well as fold change higher than 1.5 were selected as
ions of interest. These criteria enabled to highlight 86 ions
as relevant from a statistical point of view.
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Fig. 1 OPLS analyses of
plasma samples collected from
control and reGH-treated
horses. m0 coordinates of
samples from control animals
(D-7 to D-1);m1 coordinates of
samples from GH-treated
animals (D?1 to D?69).
Analyses were performed in
positive ionization mode with
mass range from 200 to 1500 m/z.
The models are based on 5086
ions (a) and 56 ions (b),
respectively. The ions are
present with different MS
abundance in the plasma
collected at D-7 to D-1, and
D?1 to D?69
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An OPLS was further performed on these 86 ions and is
presented in Fig. 4b. It reveals an efficient separation
between the samples collected on control (m0) and GH-
treated (m1) animals. Besides these satisfactory results
obtained in the negative ionization mode, it should be
specified that, and as a general rule, all the ions highlighted
during this study presented very low signal intensities
which would impose a preliminary step of concentration of
the samples before any further structural elucidation. A
cross-validation and test-permutation were performed (data
not shown) which allowed to definitively validate the
model.
A thorough examination of all candidate ions finally
selected in ESI ? and ESI- revealed that only three ions
were common to both ionization modes. The clear majority
of these potential MS signal of interest ranged from 200 to
1000 m/z, indicating that the developed analytical strategy
is as expected many suitable for detecting metabolites with
relatively low molecular weights. However, few retained
ions (observed in positive ion mode) presented m/z ratio
above 1000. Unsurprisingly, these results globally con-
firmed that potential biomarkers detected in positive and
negative ionization mode are largely complementary.
Consequently, the combination of both techniques would
allow the access to a wider range of metabolites. Last, the
chromatographic behavior observed for these potential
metabolites of interest indicated they have very polar to
relatively polar physico-chemical properties.
3.4 Comparison of metabolomic models developed
on urine and plasma matrices
Urine samples from the same animals were also analyzed
using the same analytical workflow but in positive ioni-
zation mode only (Fig. 1) as described in a previous work
(Kieken et al. 2009). The LC-HRMS data were processed
by XCMS software which allowed the detection of 5980
ions. The objective was to build an efficient and practically
operational predictive model of reGH administration and
then, to focus on a limited number of more specifically
relevant variables. The same strategy as performed on
plasma samples was then also applied on these urine
samples [i.e. OPLS analysis, S-plot examination, applica-
tion of statistical criteria for selection (P value \ 0.05,
ratio [ l1.5 l)]. Finally, 80 ions exhibiting MS intensities
responsible for differences observed between both popu-
lations were targeted among the 5980 ions constituting the
original metabolomic fingerprints (Fig. 5a). In the same
manner as analyses performed on plasma matrix, the model
was subjected to a validation. The test-permutation showed
in Fig. 5b reveals that R2(Y) and Q2(Y) decreases upon
permutation which demonstrates the model validity. A
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Fig. 2 S-Plot corresponding to OPLS analysis presented in Fig. 1a
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comparison of the models obtained after ESI? finger-
printing of urine and plasma samples lead to the conclusion
that the two biological matrices were equivalently
descriptive since similar values of R2(Y) were observed;
however, the predictive ability of the models was found
higher for plasma as attested by a higher Q2(Y) value. This
significant higher value of Q2(Y) in the plasma model may
be due to the fact that this particular matrix is less sub-
jected to large variations in its composition than urine.
Unlike plasma and most biological fluids, which exhibit
tightly controlled solutes concentrations, urine composition
is known to vary widely based upon water consumption
and other physiological factors (Warrack et al. 2009).
However, urine metabolomic model was found interesting
for its possibility to discriminate samples collected 69 days
after the first reGH administration from samples collected
on treated population which emphasize the fact that dif-
ferent metabolomes are investigated in urine and plasma.
In this context, urine seems to be more interesting for a
long-term screening of reGH abuse in horses. No common
ion of interest could be detected between urine and plasma
models, demonstrating that the nature of analyzed com-
pounds is different according to biological matrix.
Metabolites present in urine and plasma certainly exhibit
different physicochemical properties which explains why
urine matrix is more interesting for a long-term control.
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of data for the building of
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and 1 GH-treated coordinates)
populations; m1/3 data for the
prediction (j2 control and j3
GH-treated coordinates). For the
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4 Conclusions
LC-HRMS fingerprinting in positive and negative ioniza-
tion mode has been applied to plasma samples for the
assessment of the effect of reGH administration on horse
metabolism (without identifying any specific metabolites in
the profile). The comprehensive metabolomics approach
described in this paper enables to examine small molecules
up to 1500 Da in plasma samples. Through chemometric
models, modifications of horse metabolism upon reGH
administration were highlighted thanks to fingerprinting
analyses acquired in both ionization modes. Relevant
potential candidate biomarkers have been selected and
have proved their ability to discriminate control from
reGH-treated animals. However, the low MS intensity of
ions targeted in negative mode may be problematic for
further structural elucidation step where the abundance of
metabolites is a crucial criterion to obtain satisfying mass
precisions on molecular ion and its fragments. Regarding
analysis performed in the positive ionization mode, the
concentration of metabolites would be sufficiently abun-
dant to consider a chemical identification without the
development of a previous purification step. Plasmatic and
urine biological signatures were compared and revealed
dissimilarities and complementarities. Indeed, no common
ion of interest could be highlighted between the both
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Fig. 4 OPLS plasma samples
collected from control and
reGH-treated horses. m0
coordinates of samples from
control animals (D-7 to D-1);
m1 coordinates of samples from
GH-treated animals (D?1 to
D?69). Analyses were
performed in negative
ionization mode with mass
range from 200 to 1500 m/z.
OPLS models are based on 3039
ions (a) and 86 ions (b),
respectively
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models, demonstrating that metabolic pathways are not the
same in urine and plasma. However, plasma proved to be
interesting for the prediction of unknown sample and urine
more promising for long term detection. Urine and plasma
can be seen as essential matrices for the development of
metabolomics approach applied to the control of reGH
administration.
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